Videos

Susana M. Campos, MD, discusses her thoughts on the biggest advancements in ovarian cancer in 2018. PARP inhibitors are great at putting these patients in remission; however, the challenge with this lies in keeping them in remission.

Management of Metastatic Colon Cancer

Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the potential for immunotherapy/TKI combinations in the treatment of advanced renal cell carcinoma.

Eric Smith, MD, PhD, discusses the use of armored chimeric antigen receptor T cells in multiple myeloma.

Immunotherapy Potential in Locally Advanced CSCC

Steven J. Katz, MD, MPH, discusses the benefits and challenges with genetic testing in patients with breast cancer.

Hendrik-Tobias Arkenau, MD, PhD, discusses the rationale for using TAS-102 (trifluridine/tipiracil; Lonsurf) as a treatment for patients with gastric cancers.

Thor Halfdanarson, MD, discusses his takeaway message on neuroendocrine tumors (NETs) at the 2018 ISGIO Annual Conference.

Weijing Sun, MD, discusses a major topic in locally advanced gastroesophageal junction adenocarcinoma covered at the 2018 ISGIO Annual Conference in Arlington, Virginia.

James L. Wade III, MD, FACP, FASCO, discusses the importance of clinical trials in the community.